To ensure that our emails get to your inbox, please add Decision_Resources_Inc.@mail.vresp.com to your email address book or safe senders list.

If this message does not display properly, please click here to launch your browser.

Decision Resources

The Impact of Cimzia’s Launch on the U.S. Rheumatoid Arthritis Drug Market: Stealing Market Share from Other TNF-alpha Inhibitors?

— An Analyst Call from Decision Resources

Based on our 2009 Pharmacor report Rheumatoid Arthritis, Decision Resources is offering an exclusive analyst call entitled The Impact of Cimzia’s Launch on the U.S. Rheumatoid Arthritis Drug Market: Stealing Market Share from Other TNF-alpha Inhibitors? Because this presentation will feature major report updates, it is ONLY available to purchasers of this Pharmacor report.

Please contact us to learn how you can purchase this report and attend the analyst call.

Following the recent approval by the U.S. Food and Drug Administration of UCB/Otsuka’s Cimzia for rheumatoid arthritis, Decision Resources has updated its 10-year forecast for Cimzia. Featuring a specific focus on the TNF-alpha inhibitors drug class, this presentation will discuss how the launch of Cimzia—which occurred sooner than had been previously expected—will affect the rheumatoid arthritis drug market. 

This 15-minute analyst call, presented by Analyst Joanna Kim, M.Ed., will provide a new annualized forecast for the rheumatoid arthritis TNF-alpha inhibitors market in the United States.

The session will also answer the following questions as they pertain to the U.S. drug market:

  • Do interviewed experts have favorable expectations for Cimzia in the rheumatoid arthritis market, given its earlier-than-expected launch and positive label?
  • Which features of Cimzia’s label will allow the agent to compete more effectively in the rheumatoid arthritis TNF-alpha inhibitor market?
  • What are the short-term and long-term effects of Cimzia on the sales of Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen’s Simponi, Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira?
  • Will Cimzia be able to overcome the constraints of the competitive rheumatoid arthritis market?

Ms. Kim will conduct a brief live Q & A session after the presentation.

Registration

The Impact of Cimzia’s Launch on the U.S. Rheumatoid Arthritis Drug Market: Stealing Market Share from Other TNF-alpha Inhibitors?

June 2, 2009 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time

To learn how you can purchase this Pharmacor report and attend the analyst call, please contact us using the information below.

Contact Us

In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

 

Analyst Call Details

Date & Time
Tuesday, June 2, 2009
10:00 a.m. EST

Duration
15 minutes

contact sales

About the Speaker

Joanna Kim

Joanna Kim, M.Ed.

Joanna Kim, M.Ed., has spent the past five years as an analyst for the Immune and Inflammatory Disorders program at Decision Resources. Prior to joining Decision Resources, Ms. Kim was involved in medical research and education. She earned a bachelor of science degree in biology from Amherst College and a master’s degree in secondary science education from Columbia University.

Decision Resources

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2009 Decision Resources, Inc. All rights reserved.